healthcare

Avoiding a ticking timebomb

72% of investors are considering a shift in their holdings

'Sell' recommendation

Leaving a legacy for the industry and beyond

Earnings per share could drop by 5%

Fund buoyed by growth in flows towards Asia

Sector leaders key to country's return to 'normality'

Opportunities in AI and disruptive tech

Four key investment areas including genomics and digitisation

No V-shaped recovery